INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION Patent applications |
Patent application number | Title | Published |
20160120428 | DIGITALLY INVERTIBLE UNIVERSAL AMPLIFIER FOR RECORDING AND PROCESSING OF BIOELECTRIC SIGNALS - A system for measuring electrical signals in a biological subject includes a variable gain amplifier with a predetermined transfer function that generates amplified signals corresponding to an input from electrical signals in the biological subject over a predetermined range of frequencies and amplification gain levels, an analog to digital converter generating digital data corresponding to the amplified signals, and a signal processing device receiving the digital data for the plurality of amplified signals. The signal processing device applies an inversion filter with another transfer function that is an inverse of the transfer function of the variable gain amplifier to remove an effect of the transfer function from the digital data, and generates an output signal corresponding to the electrical signals in the subject with reference to the filtered digital data. | 05-05-2016 |
20160111026 | CONDUIT IDENTIFICATION SYSTEM - An identifier for a conduit includes a substrate having a pair of apertures. The substrate further contains a frangible portion encompassing one of the apertures and having a shape that corresponds to an opening left in the substrate after removal of the frangible portion. The identifier enables the shape of the frangible portion to be correlated with the shape of the opening left in the substrate after the frangible portion is separated from the substrate. | 04-21-2016 |
20150380732 | NOVEL VANADIUM OXIDE CATHODE MATERIAL - An electrode material for an electrochemical cell comprising a plurality of stacked vanadium pentoxide ribbons defining a substrate, a plurality of graphene oxide sheets infiltrating the substrate to define an electrode material, and a plurality of water molecules present between adjacent vanadium oxide ribbons. Each respective graphene oxide sheet is positioned between two adjacent vanadium pentoxide ribbons. The electrode material is about 2 weight percent graphene oxide. Water molecules are present in a ratio of at least about 0.3 water molecules per V | 12-31-2015 |
20150376256 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 12-31-2015 |
20150374795 | O-GLYCOSYLATED CARBOXY TERMINAL PORTION (CTP) PEPTIDE-BASED INSULIN AND INSULIN ANALOGUES - Compositions and formulations comprising insulin or insulin analogues comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-188 to 142 of the beta subunit of human chorionic gonadotropin (hCGβ) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analogue is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogues are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogues comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans. | 12-31-2015 |
20150299285 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES - Insulin analogs comprising a non-native glycosylation site sequence are provided having high potency and specificity for the insulin receptor. In one embodiment a peptide sequence of greater than 18 amino acids is used as a linking moiety to link human insulin A and B chains, or analogs or derivatives thereof, to provide high potency single chain insulin analogs. In one embodiment the linking moiety comprises one or more glycosylation sites. Also disclosed are prodrug and conjugate derivatives of the insulin analogs. | 10-22-2015 |
20150290206 | Use of TRPV4 Antagonists to Ameliorate Hydrocephalus and Related Materials and Methods - The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein. | 10-15-2015 |
20150274802 | INSULIN ANALOG DIMERS - Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the first and second insulin polypeptide are independently a two chain insulin analog or a single chain analog and the first and second insulin polypeptides are linked to one another via a B29-B29′, B1-C8, B1-B1 or C8-C8 linkage. | 10-01-2015 |
20150218182 | MODULATORS OF VIRUS ASSEMBLY AS ANTIVIRAL AGENTS - In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described. | 08-06-2015 |
20150202169 | NOVEL REGULATORS OF ALDEHYDE DEHYDROGENASE ALDH3A1 AND RELATED THERAPEUTIC METHODS - Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to cancer chemotherapeutic agents that are degraded by ALD3H1. The compositions described herein act as competitive inhibitors of ALD3H1 and thereby reduce breakdown of chemotherapeutics by this enzyme, and increase their efficacy for cancer treatment. | 07-23-2015 |
20150188233 | ARTIFICIAL SKIN FOR RADAR MANNEQUINS - An artificial skin for use on a radar mannequin exposed to electromagnetic radiation having a predetermined frequency and a radar mannequin having the artificial skin are provided. The artificial skin and the radar mannequin with the artificial skin are configured to produce a radar cross section that closely approximates the radar cross section of a human. The artificial skin includes a conductive layer of material and a shielding layer of material. The conductive layer and the shielding layer are configured to reflect electromagnetic radiation at a level of an electromagnetic response of human skin exposed to the electromagnetic radiation. The shielding layer also electromagnetically shields an inside surface of the artificial skin from electromagnetic radiation. | 07-02-2015 |
20150086077 | SYSTEM AND METHOD OF ALERTING A DRIVER THAT VISUAL PERCEPTION OF PEDESTRIAN MAY BE DIFFICULT - A pedestrian perception alert system configured to issue a warning during real-time when a driver's visual detection of a pedestrian is difficult, and a method thereof is provided. The system includes a video camera, an alert for issuing a warning, a processor, and a Pedestrian Detection Unit (“PDU”). The PDU analyzes the video camera image to detect a pedestrian. A Global Clutter Analysis Unit (“GCAU”) generates a global clutter score. A Local Pedestrian Clutter Analysis Unit (“LPCAU”) generates a local pedestrian clutter score. The processer processes the global clutter score and local pedestrian clutter score so as to generate a pedestrian detection score. The alert is actuated when the pedestrian detection score is outside of a predetermined threshold so as to notify the driver that perception of a pedestrian is difficult at that time. | 03-26-2015 |
20140371081 | Compositions for and Methods of Detecting, Diagnosing, and Prognosing Thymic Cancer - Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers. | 12-18-2014 |
20140364453 | SALUBRINAL-DRIVEN ATTENUATION OF MALIGNANT PHENOTYPES OF 4T1 BREAST CANCER CELLS - A method is disclosed for the in vivo treatment of a breast cancer tumor utilizing a therapeutically effective amount of an agent that inactivates the Rac1 GTPase and results in a reduction in cancer cell invasion, reduced cancer cell motility, and reduced volume and weight of the tumor. Agents that can be used in this treatment include salubrinal, guanabenz, and combinations thereof. The agents additionally have proven useful in reducing the development of osteoclastogenesis and reducing bone metastasis. | 12-11-2014 |
20140336446 | CAVOPULMONARY VISCOUS IMPELLER ASSIST DEVICE AND METHOD - A bearingless and sealless rotary blood pump is disclosed which provides multidirectional flow intended to provide low-pressure, high-volume right-sided partial assist circulatory support in a univentricular Fontan circulation on a permanent basis. The pump includes a housing and an impeller suspended in the center of the housing. The housing incorporates flow optimization features between inlet and outlet ends, as well as with the impeller surface. Large fluid gaps maintained between impeller and housing eliminate any potential for blood flow obstruction. The impeller contains some motor components. It includes a central stator and surrounding rotor. The motor includes a brushless DC outrunner electrical motor design. An electromagnetic stator core is surrounded by a circumferential passive magnetic ring. The rotor is further levitated about the stator spindle by a plurality of axially and radially located passive magnetic and hydrodynamic journal bearings on both ends of the spindle. The rotor is bearingless and sealless. During impeller rotation, blood entering the space between the rotor and stator is induced to flow by centrifugal pumping action and the fluid film separates the stator hydrodynamic bearings from the rotor so that there is no direct mechanical contact between the rotor and stator. | 11-13-2014 |
20140336128 | GIGAXONIN FUSION PROTEIN AND METHODS FOR TREATING GIANT AXONAL NEUROPATHY - The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells. | 11-13-2014 |
20140248646 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME - A fluorophore and methods of detecting cations and hydrophobic environments using the fluorophore are disclosed. The fluorophore includes an imidazo[1,5-a]pyridinium ion core and has the formula | 09-04-2014 |
20140221283 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 08-07-2014 |
20140213805 | NOVEL ARYLALCOHOLS AND METAL COMPLEXES THEREOF - Provided herein is a compound of Formula 1: | 07-31-2014 |
20140212419 | ESTER-BASED INSULIN PRODRUGS - Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 07-31-2014 |
20140206607 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 07-24-2014 |
20140142679 | INTRAVASCULAR SHUNT FOR TRAUMATIZED ARTERIES - The present invention relates to a catheter assembly including a catheter body, a first and a second set of a plurality of fenestrations, a first and a second inflatable device, a first and a second pleat, at least one obstructing stop near each end portion of the catheter body, and a first and a second flexible tube connected to the first and the second inflatable device. The catheter assembly further includes a pumping device in communication with the first and the second inflatable device via the first and the second flexible tube. The catheter assembly is used to restore blood flow to a traumatized blood vessel. | 05-22-2014 |
20140138538 | RESOLUTION AND MASS RANGE PERFORMANCE IN DISTANCE-OF-FLIGHT MASS SPECTROMETRY WITH A MULTICHANNEL FOCAL-PLANE CAMERA DETECTOR - A distance-of-flight mass spectrometer (DOFMS) includes an ion source, a field-free region, an extraction region in which ions are accelerated, and a spatially-selective detector for spatially selectively detecting ions extracted by the extraction region. A method for operating a distance-of-flight mass spectrometer DOFMS comprises controlling a detection time in such a way as to permit ions with progressively greater mass-to-charge (m/z) ratios to enter the extraction region of the DOFMS at positions which will permit the ions with progressively greater m/z ratios to enter the detector of the DOFMS, generating a component mass spectrum at each selected value of detection time, and then assembling a composite mass spectrum by shifting the distance-of-flight axis of each component mass spectrum by a distance corresponding to the change in detection time. | 05-22-2014 |
20140135507 | TOTAL SYNTHESIS OF ARTEMISININ - The present invention provides a method for manufacturing artemisinin and its congeners from cyclohexenone as a starting material. | 05-15-2014 |
20140128398 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS - Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein. | 05-08-2014 |
20140120067 | MUSCLE STEM CELL THERAPY FOR TREATMENT OF DYSPHAGIA - Described herein is a method for the treatment of dysphagia, comprising administering a therapeutically effective dose of an isolated muscle-derived stem cell population into a muscle involved in swallowing, such as tongue, pharynx, palate, and strap muscles. | 05-01-2014 |
20140112960 | VISIBLE LIGHT CURABLE HYDROGELS AND METHODS FOR USING - This disclosure provides compositions comprising a visible light-curable mixture capable of forming a biocompatible hydrogel, hydrogels prepared from the hydrogel precursor mixtures, and a biocompatible delivery system comprising a hydrogel. The disclosure also provides a process for preparing a multi layer hydrogel delivery system. | 04-24-2014 |
20140107222 | TREATMENTS FOR SOCIAL LEARNING DISORDERS - The use of Pak1 inhibitors to treat social or learning disabilities is disclosed. In one embodiment patients exhibiting social or learning disabilities as well as abnormally low NF1 activity are administered PAK inhibitors to treat the social or learning disabilities. Reductions in PAK activity have been found to ameliorate the effects of aberrant neurofibromatosis type 1 activity. | 04-17-2014 |
20140107021 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY - Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided. | 04-17-2014 |
20140094464 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES - The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases. | 04-03-2014 |
20140075183 | SECURE AND SCALABLE MAPPING OF HUMAN SEQUENCING READS ON HYBRID CLOUDS - System and methods are provided for performing privacy-preserving, high-performance, and scalable DNA read mapping on hybrid clouds including a public cloud and a private cloud. The systems and methods offer strong privacy protection and have the capacity to process millions of reads and allocate most of the workload to the public cloud at a small overall cost. The systems and methods perform seeding on the public cloud using keyed hash values of individual sequencing reads' seeds and then extend matched seeds on the private cloud. The systems and methods are designed to move the workload of read mapping from the extension stage to the seeding stage, thereby ensuring that the dominant portion of the overhead is shouldered by the public cloud. | 03-13-2014 |
20140065465 | SODIUM CHALCOGENIDE ELECTRODES FOR SODIUM BATTERIES - A sodium-ion electrochemical cell described herein comprises a cathode, an anode, and a non-aqueous sodium-containing electrolyte therebetween. The electrolyte comprises a sodium salt dissolved in a liquid organic carrier. The cathode comprises at least one transition metal chalcogenide compound in an initial discharged or partially discharged state and having the formula Na | 03-06-2014 |
20140051834 | Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function - Herein is reported an Fc-region fusion polypeptide or Fc-region conjugate comprising one to four incretin receptor ligand polypeptides and a variant human Fc-region with a mutation of the amino acid residue at position 329 and at least one further mutation of at least one amino acid selected from the group comprising amino acid residues at position 228, 233, 234, 235, 236, 237, 297, 318, 320, 322 and 331 to a different residue, wherein the residues in the Fc-region are numbered according to the EU index of Kabat and its use as a medicament. | 02-20-2014 |
20140039003 | TREATMENT OF GLAUCOMA - A method is provided for treating patients suffering from elevated intraocular pressure or fluctuation in intraocular pressure, including for example glaucoma patients. The method comprises administering to the patient an inhibitor of orexin activity in an amount sufficient to reduce intraocular pressure or intraocular pressure fluctuation in one or both eyes of the patient. | 02-06-2014 |
20140021028 | BIOMASS GASIFICATION/PYROLYSIS SYSTEM AND PROCESS - A system and process capable of promoting the energy content of a syngas produced from a biomass material. The system and process entail compacting a loose biomass material and simultaneously introducing the compacted biomass material into an entrance of a reactor tube, and then heating the compacted biomass material within the tube to a temperature at which organic molecules within the biomass material break down to form ash and a fuel gas mixture. The fuel gas mixture is withdrawn from the tube and the ash is removed from the tube through an exit thereof. The entrance and exit of the tube, the compaction step, and the removal step cooperate to inhibit ingress of air into the tube by forming a plug of the biomass material at the entrance of the tube and a plug of ash at the exit of the tube. | 01-23-2014 |
20130345231 | ANTICANCER THERAPEUTIC AGENTS - The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy. | 12-26-2013 |
20130345117 | PEPTIDE-PHOSPHOLIPID CONJUGATES - The present invention provides a peptide-phospholipid conjugate of Formula 1: | 12-26-2013 |
20130338144 | uPAR-uPA INTERACTION INHIBITORS AND METHODS FOR TREATING CANCER - The invention described herein pertains to compounds, compositions and formulations comprising the compounds, and methods for use of the compounds, compositions and/or formulations in the treatment of diseases responsive to the inhibition of uPAR-uPA interactions, such as cancer. | 12-19-2013 |
20130338077 | GLUCOCORTICOID INDUCED LEUCINE ZIPPER MIMETICS AS THERAPEUTIC AGENTS IN MULTIPLE SCLEROSIS - Polypeptide compositions that mimic the activity of glucocorticoid induced leucine zipper (GILZ) on the immune system are described. Also described is a method of treating multiple sclerosis using compositions comprising GILZ or lower molecular weight polypeptides with structural relationships to GILZ. | 12-19-2013 |
20130324615 | BIODEGREDATION SUPPRESSION SOLUTION FOR FORENSIC SAMPLES - A biodegradation suppression system may include an anti-microbial agent, wherein the anti-microbial agent is effective to suppress biodegradation of ignitable liquid residues within a forensic sample. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of ignitable liquid residues within a forensic sample for a period of time. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of gasoline, wherein the solution is effective to allow for identification of at least one component of gasoline within the forensic sample. | 12-05-2013 |
20130292562 | ION MOBILITY SPECTROMETER AND METHOD OF OPERATING SAME - An ion mobility spectrometer instrument has a drift tube that is partitioned into a plurality of cascaded drift tube segments. A number of electric field activation sources may each be coupled to one or more of the plurality of drift tube segments. A control circuit is configured to control operation of the number of electric field activation sources in a manner that sequentially applies electric fields to the drift tube segments with a activation duration of at least one of the electric field activation sources different than that of the others to allow only ions having a predefined ion mobility or range of ion mobilities to travel through the drift tube. The drift tube segments may define a linear drift tube or a closed drift tube with a continuous ion travel path. | 11-07-2013 |
20130275094 | DEDUCTIVE MULTISCALE SIMULATION USING ORDER PARAMETERS - Illustrative embodiments of systems and methods for the deductive multiscale simulation of macromolecules are disclosed. In one illustrative embodiment, a deductive multiscale simulation method may include (i) constructing a set of order parameters that model one or more structural characteristics of a macromolecule, (ii) simulating an ensemble of atomistic configurations for the macromolecule using instantaneous values of the set of order parameters, (iii) simulating thermal-average forces and diffusivities for the ensemble of atomistic configurations, and (iv) evolving the set of order parameters via Langevin dynamics using the thermal-average forces and diffusivities. | 10-17-2013 |
20130236842 | Pilot Fuel Injection for a Wave Rotor Engine - Apparatus and methods for combustion of fuel includes, in some embodiments, a fuel nozzle which injects fuel into a combustion channel of a wave rotor combustor or a pulse detonation combustor. In some embodiments the combustion process includes a backward-propagating detonation wave within a substantially closed channel which compresses discrete quantities of combustible and noncombustible mixture. Yet other embodiments include a precombustion chamber integrated into the wave rotor, the outlet stator or both. | 09-12-2013 |
20130210698 | MATERIALS AND METHODS FOR SUPPRESSING INFLAMATORY AND NEUROPATHIC PAIN - N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2′,3′-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.2 function suppressed inflammatory and neuropathic nociception, providing a method for treating pain and inflammation. | 08-15-2013 |
20130203665 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR - Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs. | 08-08-2013 |
20130203660 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). | 08-08-2013 |
20130202717 | MATERIALS AND METHODS FOR DIAGNOSING AND PREDICTING THE COURSE OF PROSTATE CANCER - Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p<0.0001). FOXA1 expression correlated positively with tumor size, extra-prostatic extension, angiolymphatic invasion, AR and metastasis but did not correlate with age, tumor stage, Gleason score, presence of PIN or multifocality, seminal vesicle or perineural invasion and status of surgical excision margins. Expression of GATA-3 was not seen in either normal epithelium or tumor. High FOXA1 expression is associated with development of metastatic prostate cancer. Accordingly, FOXA1 expression can be used to classify patients at higher risk for metastases. | 08-08-2013 |
20130184244 | PROCESS FOR PREPARING DELTA-7,9(11) STEROIDS FROM GANODERMA LUCIDUM AND ANALOGS THEREOF - Processes for preparing lanostane triterpenes from the medicinal mushroom | 07-18-2013 |
20130157934 | Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity - Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 06-20-2013 |
20130149349 | USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING - TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals. | 06-13-2013 |
20130142829 | Mutant Parasites for Use as Vaccines and Platforms for Screening for Compounds - Cloning and characterization of a TgIF2α kinase from | 06-06-2013 |
20130137849 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 05-30-2013 |
20130135110 | ADVANCED BATTERY EARLY WARNING AND MONITORING SYSTEM - Systems, apparatuses and methods for detecting internal cell faults using online and real-time sensing techniques, and providing an accurate and reliable early warning for the incoming failure of battery cells hours or days prior to failure. A system is configured to perform real-time and direct measurement of battery cell parameters of temperature, voltage, and AC impedance through online sensing. These parameters may be simultaneously processed using advanced probabilistic and/or fuzzy logic-based algorithms to provide an early warning for the incoming failure of battery cells in a battery pack. This technology may safeguard the LIB battery packs while allowing them to operate at or near 100% capacity in both transportation and stationary applications. | 05-30-2013 |
20130123462 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS - Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 05-16-2013 |
20130123178 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY - Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 05-16-2013 |
20130116173 | Glucagon Analogs Exhibiting GIP Receptor Activity - Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range. | 05-09-2013 |
20130112263 | LAYER-BY-LAYER NANOASSEMBLED NANOPARTICLES BASED THIN FILMS FOR SOLAR CELL AND OTHER APPLICATIONS - A solar cell. The solar cell includes a substrate, a first layer comprising a first copper-based material deposited upon the substrate, the first copper-based material electrically attracted to the substrate or to a first optional deposit layer deposited between the substrate and the first layer, and a second layer comprising a second copper-based material deposited upon the first layer or an second optional deposit layer deposited between the first layer and the second layer, the second copper-based material electrically attracted to the first layer or to the second optional deposit layer, wherein the first copper-based material and the second copper-based material are selected from the group consisting of copper indium gallium (di)selenide (CIGS), copper indium selenium (CIS), and cadmium sulfate (CdS). | 05-09-2013 |
20130101518 | METHOD AND APPARATUS FOR KIDNEY FUNCTION ANALYSIS - A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface. | 04-25-2013 |
20130065972 | METHODS FOR SCREENING Th2 INFLAMMATORY DISEASES - The present invention provides a method for screening for a Th2 inflammatory disease in a subject comprising the steps of: assaying a miR-21 expression level in a biological sample from the subject, and comparing the miR-21 expression level in the biological sample from the subject to the miR-21 expression level in a control, wherein an increase in the miR-21 expression level in the biological sample from the subject compared to the miR-21 expression level in the control indicates the presence of Th2 inflammatory disease in the subject. | 03-14-2013 |
20130053557 | PROCESSES FOR PREPARING LINEZOLID - Processes and intermediates for preparing linezolid, and pharmaceutically acceptable salts thereof, are described herein. | 02-28-2013 |
20130047274 | CD4 T-CELLS INVOLVED IN MAMMALIAN HOST RESPONSE TO EPITHELIAL CELL INFECTIONS AND USES THEREOF - MHC class II-restricted | 02-21-2013 |
20130045947 | PLA2ACTIVITY AS A MARKER FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS - Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA | 02-21-2013 |
20130028989 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF - Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment. | 01-31-2013 |
20130004469 | ENGINEERED LUMENIZED VASCULAR NETWORKS AND SUPPORT MATRIX - Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications. | 01-03-2013 |
20120329708 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 12-27-2012 |
20120329707 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 12-27-2012 |
20120322725 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY - Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided. | 12-20-2012 |
20120315253 | METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS - The receptor EP | 12-13-2012 |
20120288511 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon receptor and the GLP-I receptor. In some embodiments, the glucagon analog exhibits at least 100% or more of the activity of native glucagon at the glucagon receptor and/or at least 100% or more of the activity of native GLP-I at the GLP-I receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is within 50-fold or less than the EC50 at the glucagon receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is two- to ten-fold greater than the EC50 at the glucagon receptor. Related conjugates, dimers and multimers, and pharmaceutical compositions, and uses thereof, are further provided. | 11-15-2012 |
20120282641 | METHOD OF IDENTIFYING PEPTIDES - Methods of identifying polypeptides have been developed using a de novo sequencing technique. Methods use photodissociation and low-energy fragmentation and the spectra of peptide ions obtained therefrom, such as obtained by post-source decay (PSD), have been developed. The methods include photodissociation and the spectra therefrom obtainable from treating ions with predetermined wavelengths of radiation in the vacuum ultraviolet range of the electromagnetic spectrum. The confidence of amino acid assignments based on x-type ions is evaluated by observing complementary y-, v- and w-type ions that provide additional constraints to sequence identification. | 11-08-2012 |
20120279570 | SOLUBLE GRAPHENE NANOSTRUCTURES AND ASSEMBLIES THEREFROM - Disclosed herein is a method for preparing large soluble graphenes. The method comprises attaching one or more hindering groups to the graphene, which can prevent face-to-face graphene stacking by reducing the effects of inter-graphene attraction. The large graphenes can absorb a wide spectrum of light from UV to near infrared, and are useful in photovoltaic devices and sensitizers in nanocrystalline solar cells. | 11-08-2012 |
20120269810 | METHODS AND COMPOSITIONS FOR PANIC DISORDERS - Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed. | 10-25-2012 |
20120258482 | PCNA METHYLTRANSFERASE - Proliferating cell nuclear antigen (PCNA)-dependent glutamate methyltransferases are disclosed that can methylesterify one or more glutamic acid or aspartic acid residues of PCNA. | 10-11-2012 |
20120252907 | DIAGNOSTIC METHODS AND KIT FOR DETECTING CANCER - The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual. | 10-04-2012 |
20120196804 | GLUCAGON ANALOGS EXHIBITING PHYSIOLOGICAL SOLUBILITY AND STABILITY - Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both. | 08-02-2012 |
20120195906 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3. | 08-02-2012 |
20120167898 | Patient Immobilization Device For Radiotherapy Treatment System And Methods - A patient immobilization device for radiotherapy includes a one-piece composite body having a core and a carbon fiber reinforced skin encapsulating the core. The composite body further includes a posterior surface configured for mounting the composite body upon a radiotherapy support table, and an anterior surface defining a cradle. Positioning a patient upon the immobilization device and supporting the patient with the cradle enables emitting therapeutic radiation towards a craniospinal treatment site of the patient from a posterior side of the immobilization device while the patient is supported in a supine position. The emitted radiation may include proton beam radiation. | 07-05-2012 |
20120100112 | MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present invention provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor. | 04-26-2012 |
20120093776 | METHODS FOR TREATING DISEASES USING A BONE MORPHOGENETIC PROTEIN - Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue. | 04-19-2012 |
20120059305 | ARTERIOVENOUS SHUNT WITH INTEGRATED SURVEILLANCE SYSTEM - A hemodialytic angioacess device for implantation in dialysis patients, comprising an arteriovenous (AV) shunt, anastomotic valves that connect the AV shunt to blood vessels, a valve control system and an integrated surveillance system that measures flow conditions in the blood vessels at the AV shunt, preferably when the valves are closed and the patient is not undergoing dialysis treatment. The flow condition data, which may include data representing the flow rate, pressure, volume and velocity of blood flowing through the vessels, is stored in a memory and transmitted to a health care provider or technician on demand. The data can be used to calculate and monitor important physiological parameters, such as compliance and resistance, for the blood vessels, and help detect and identify dangerous conditions, such as turbulence and stasis, which can contribute to AV shunt failure, vessel injury and other serious complications for the patient. | 03-08-2012 |
20120011156 | INTER-CLASS MOLECULAR ASSOCIATION CONNECTIVITY MAPPING - Methods, systems, devices and/or apparatuses are provided for computationally deriving molecular association connectivity maps for the study of inter-class molecular associations in toxicogenomics and drug discovery applications. The inter-class molecular associations can be between at least one bio-molecular entity and at least one therapeutic agent. The methods, systems, devices and/or apparatuses apply integrated molecular interaction network mining and text mining techniques. | 01-12-2012 |
20110311453 | Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto - An alloyed semiconductor quantum dot comprising an alloy of at least two semiconductors, wherein the quantum dot has a homogeneous composition and is characterized by a band gap energy that is non-linearly related to the molar ratio of the at least two semiconductors; a series of alloyed semiconductor quantum dots related thereto; a concentration-gradient quantum dot comprising an alloy of a first semiconductor and a second semiconductor, wherein the concentration of the first semiconductor gradually increases from the core of the quantum dot to the surface of the quantum dot and the concentration of the second semiconductor gradually decreases from the core of the quantum dot to the surface of the quantum dot; a series of concentration-gradient quantum dots related thereto; in vitro and in vivo methods of use; and methods of producing the alloyed semiconductor and concentration-gradient quantum dots and the series of quantum dots related thereto. | 12-22-2011 |
20110288003 | AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS - Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 11-24-2011 |
20110245164 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR - Insulin-like growth factor analogs are disclosed wherein substitution of the IGF native amino acids, at positions corresponding to positions B16 and B17 of native insulin, with tyrosine and leucine, respectively, increases potency of the resulting analog at the insulin receptor by tenfold. Also disclosed are prodrug and depot formulations of the IGF analogs, wherein the IGF analog has been modified by the linkage of a dipeptide to the analog through an amide bond linkage. The prodrug and depot formulations disclosed herein have extended half lives of at least 2 hours, 10 hours, and more typically greater than 2 are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 10-06-2011 |
20110237493 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 09-29-2011 |
20110217258 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma - Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described. | 09-08-2011 |
20110195510 | csPCNA Isoform Modifications And Uses Thereof - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 08-11-2011 |
20110183356 | METHOD TO IDENTIFY PATIENTS AT RISK FOR LUNG TRANSPLANT REJECTION - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 07-28-2011 |
20110166062 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY - Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided. | 07-07-2011 |
20110142846 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3. | 06-16-2011 |
20110098217 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY - Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized. | 04-28-2011 |
20110098188 | BLOOD BIOMARKERS FOR PSYCHOSIS - A plurality of biomarkers determine the diagnosis of psychosis based on the expression levels in a sample such as blood. Subsets of biomarkers predict the diagnosis of delusion or hallucination. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of psychosis are provided. | 04-28-2011 |
20110015386 | PERMETHYLATION OF OLIGOSACCHARIDES - A solid-phase permethylation procedure is described. For example, solid-phase permethylation can be utilized to prepare permethylated linear and branched, neutral and sialylated oligosaccharides, which can be analyzed by MALDI-MS. | 01-20-2011 |
20100331246 | ESTER-BASED INSULIN PRODRUGS - Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 12-30-2010 |
20100203058 | DIAGNOSTICS AND THERAPEUTICS BASED ON CIRCULATING PROGENITOR CELLS - Methods and compositions for detection, diagnosis, and therapeutics of arterial diseases based on pro-angiogenic and non-angiogenic circulating hematopoietic stem and progenitor cells (CHSPCs) and circulation endothelial colony forming cells (ECFCs) are described. | 08-12-2010 |
20100193678 | APPARATUS AND METHODS FOR ANALYZING IONS - An apparatus ( | 08-05-2010 |
20100190699 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS - Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs. | 07-29-2010 |
20100128221 | LASER SCANNING DIGITAL CAMERA WITH PUPIL PERIPHERY ILLUMINATION AND POTENTIAL FOR MULTIPLY SCATTERED LIGHT IMAGING - A portable, lightweight digital imaging device uses a slit scanning arrangement to obtain an image of the eye, in particular the retina. In at least one embodiment, a digital retinal imaging device includes an illumination source operable to produce a source beam, wherein the source beam defines an illumination pathway, a scanning mechanism operable to cause a scanning motion of the illumination pathway in one dimension with respect to a target, an optical element situated within the illumination pathway, the optical element operable to focus the illumination pathway into an illumination slit at a plane conjugate to the target, wherein the illumination slit is slit shaped, a first two dimensional detector array operable to detect illumination returning from the target and acquire one or more data sets from the detected illumination, wherein the returning illumination defines a detection pathway, and a shaping mechanism positioned within the illumination pathway, wherein the shaping mechanism shapes the source beam into at least one arc at a plane conjugate to the pupil. In at least one exemplary embodiment, the digital retinal imaging device is operable to minimize at least one aberration from the optical element or an unwanted reflection from the target or a reflection from a device. | 05-27-2010 |
20100068717 | CANCER THERAPY PROGNOSIS - Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making. | 03-18-2010 |
20100035297 | METHODS AND COMPOSITIONS FOR VASCULOGENIC POTENTIAL DETERMINATION - Methods and compositions to evaluate the therapeutic vasculogenic potential of a variety of cells including endothelial cells using a monolayer of pericytic cells are disclosed. Pericytic cells or mural cells including those isolated from adipose tissue, such as for example, adipose stromal cells (ASC) or adipose-derived stromal cells (ADSCs) provide suitable conditions that stimulate endothelial cells from different origins to modulate stable vascular network organization in an in vitro experimental setting. Compositions that contain premixed ASC and EC are suitable for testing a candidate agent's angiogenic or antiangiogenic potential. | 02-11-2010 |
20090029359 | DIAGNOSTIC METHODS FOR EARLY CANCER DETECTION - The present disclosure is directed to compositions and methods for detecting signs of telomere dysfunction as diagnostic indicators of metastatic disease. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect elevated expression of TRK2 protein or detect the presence of telomere fusions as an early diagnostic test for cancerous or pre-cancerous cells. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual. | 01-29-2009 |
20090017013 | MOLECULES FOR THE TREATMENT OF LUNG DISEASE INVOLVING AN IMMUNE REACTION TO CONNECTIVE TISSUE FOUND IN THE LUNG - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 01-15-2009 |
20090006001 | EMPIRICAL QUANTITATIVE APPROACHES FOR PSYCHIATRIC DISORDERS PHENOTYPES - Psychiatric phenotypes as currently defined are primarily the result of clinical consensus criteria rather than empirical research. A novel approach to characterizing psychiatric phenotypes is presented herein, termed PhenoChipping. A massive parallel profiling of cognitive and affective state is done with a PhenoChip composed of a battery of existing and new quantitative psychiatric rating scales, as well as hand neuromotor measures. Phenotypic overlap among, as well as phenotypic heterogeneity within, the three major psychotic disorders studied were demonstrated. Empirically derived clusterings of (endo)phenotypes and of patients serve genetic, pharmacological, and imaging research, as well as clinical practice. | 01-01-2009 |
20080312418 | Antibody Specific for Human 4-1BB Receptor - The human receptor H4-1BB has been isolated, sequenced and disclosed herein. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immume system during organ transplantation. A monoclonal antibody against H4-1BB can be used to enhance T-cell proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody. Tumors transfected with H4-1BBL may be capable of delivering antigen-specific signals as well as the co-stimulatory signals and can be killed by human cytotoxic T lymphocytes. | 12-18-2008 |
20080293845 | Biodegradable Implant Polymers and Composites - Biodegradable oligomeric polyesters based upon hydroxy acids, such as glycolic acid (GA), lactic acid (LLA), and copolymers thereof are described. Composites that include biodegradable polyesters and bioabsorbable fillers are also described. The described polymers and composites are injectable and in situ curable. | 11-27-2008 |